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Abstract
Background:  Cardiovascular  diseases  (CVD)  are  the  most  important  cause  of  mortality  in  Latin
America, while  peripheral  arterial  disease  (PAD)  is the  third  leading  cause  of  atherosclerotic
cardiovascular  morbidity.
Objective:  To  establish  the  prevalence  of  PAD  and  the  distribution  of  traditional  CVD  risk  factors
in a  population  from  the  Department  of  Cauca,  Colombia.
Methods:  A  cross-sectional  study  was  conducted  on  a  total  of 10,000  subjects  aged  ≥40  years,
from 36  municipalities.  An  ankle--brachial  index  (ABI)  ≤ 0.9  in either  leg  was  used  as  diagnostic
criterion of  PAD.
Results:  Overall  PAD  prevalence  was  4.4%  (4.7%  females  vs.  4.0%  males),  with  diabetes  being  the
most prevalent  risk  factor  (23%).  Among  individuals  self-reporting  a  history  of  acute  myocar-
dial infarction  or  stroke,  PAD  prevalence  was  31.0%  and  8.1%,  respectively.  After  adjusting
for potential  confounders,  PAD  was  significantly  associated  with  hypertension  (OR  4.6;  95%  CI;
3.42--6.20),  diabetes  (4.3;  3.17--5.75),  dyslipidaemia  (3.1;  2.50--3.88),  obesity  (1.8;  1.37--2.30),
and cigarette  smoking  (1.6; 1.26--1.94).  Analysis  for  the  interaction  of  risk  factors  showed  that
diabetes,  dyslipidaemia,  and  obesity  accounted  for  13.2  times  the risk  for  PAD  (6.9--25.4),  and
when adding  hypertension  to  the  model,  the  risk  effect  was  the  highest  (17.2;  8.4--35.1).
Conclusions:  Hypertension,  diabetes,  dyslipidaemia,  and  obesity,  but  not  smoking  were  strong
predictors  of  PAD.  ABI  measurement  should  be  routinely  performed  as  a  screening  test  in
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intermediate  and  high-risk  patients  for  CVD  prevention.  This  could  lead  to  an  early  intervention
and follow-up  on  populations  at risk, thus,  contributing  to  improve  strategies  for  reducing  CVD
burden.
© 2017  Published  by  Masson  Doyma  Me´xico  S.A.  on behalf  of  Instituto  Nacional  de  Cardi-
olog´ıa Ignacio  Cha´vez.  This  is  an  open  access  article  under  the  CC BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Resumen
Antecedentes:  Las enfermedades  cardiovasculares  (ECV)  son  la  causa  más  importante  de mor-
talidad en  América  Latina,  mientras  que  la  enfermedad  arterial  periférica  (EAP)  es  la  tercera
causa de  morbilidad  cardiovascular  aterosclerótica.
Objetivos:  Establecer  la  prevalencia  de  la  EAP y  la  distribución  de factores  de  riesgo  tradi-
cionales  para  ECV  en  una  población  del departamento  del  Cauca,  Colombia.
Métodos:  Se  realizó  un estudio  de  corte  transversal  en  un total  de 10,000  sujetos  ≥ 40  an˜os  de
36 municipios.  Un  índice  tobillo-brazo  ≤ 0.9  en  cualquiera  de las  piernas  fue  utilizado  como
criterio de  diagnóstico  para  EAP.
Resultados:  La  prevalencia  de  EAP  fue  del 4.4%  (4.7%  en  mujeres  vs.  4%  en  hombres),  siendo
la diabetes  el  factor  de  riesgo  más prevalente  (23%).  Entre  los  individuos  con  autorreporte  de
infarto agudo  de  miocardio  y  accidente  cerebrovascular,  la  prevalencia  de EAP  fue  del  31%  y
8,1%, respectivamente.  Después  del  ajuste  por  potenciales  factores  de  confusión,  la  EAP  estuvo
asociada  significativamente  con  hipertensión  (OR:  4.6;  IC  95%:  3.42-6.20),  diabetes  (4.3;  3.17-
5.75), dislipidemia  (3.1;  2.50-3.88),  obesidad  (1.8;  1.37-2.30)  y  consumo  de  cigarrillo  (1.6;
1.26-1.94). El  análisis  de interacción  entre  los  factores  de riesgo  mostró  que  diabetes,  dislipi-
demia  y  obesidad  presentaron  13.2  veces  más  riesgo  para  EAP  (6.9-25.4),  y  cuando  se  agregó
hipertensión  al  modelo,  el  riesgo  fue  el más  alto  (17.2;  8.4-35.1).
Conclusiones:  La  medición  del  índice  tobillo-brazo  debe  realizarse  de  forma  rutinaria  en
pacientes con  riesgo  intermedio/alto  como  prueba  de  cribado  para  la  prevención  de  ECV,
permitiendo  la  intervención  temprana  y  el seguimiento  de  las  poblaciones  en  situación  de riesgo.
© 2017  Publicado  por  Masson  Doyma  Me´xico  S.A. en  nombre  de Instituto  Nacional  de  Cardi-
olog´ıa Ignacio  Cha´vez.  Este  es un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Peripheral  arterial  disease  (PAD),  after acute  myocar-
dial  infarction  and  stroke,  is  the  third  leading  cause
of  atherosclerotic  cardiovascular  morbidity  and  mortality
worldwide.  It is  estimated  that  202 million  people  in the
world  are  affected  with  PAD,  from  whom  45  million  are
expected  to die from  coronary  or  cerebrovascular  disease
during  a  10-year  period.1 Although  the number  of  individ-
uals  with  PAD  has  increased  over the last decade  by 28.7%  in
low  or  middle  income  countries,1 few epidemiological  stud-
ies  have  been  conducted  to  establish  reliable  estimates  of
prevalence  and distribution  of  risk  factors;  specially  in Latin
America,  where  cardiovascular  diseases  (CVD)  have  become
the  leading  cause  of  death  and  disability.2 Therefore,  studies
are  still  needed  for  a better  understanding  of  the  etiology
and  disease  distribution,  and  for  developing  more  effective
policies  and  programs  for  preventing  and  managing  PAD.
The  ankle--brachial  index  (ABI),  the ratio  of the  ankle  and
brachial  systolic  blood  pressures,  is  often  used as  a surrogate
marker  for  PAD.  An  ABI  of  0.9  or  less  is  generally  considered
abnormal  and  suggests  PAD.3 The  ABI  is  currently  considered
the  most  effective  tool  to  screen  PAD,  being  particularly
important  in detecting  PAD  in asymptomatic  individuals.4
In fact,  it has  been  suggested  that  ABI  measurement  may
reduce  morbidity  and  mortality  through  the early  detec-
tion  and  treatment  of  PAD  and  other  CVD.2--4 Furthermore,
population-based  cohort  studies  have  established  the ABI  as
an  independent  risk  indicator  of atherothrombotic  events
and  as  a  risk  predictor  of CVD.4--6
In  Colombia,  CVD  has a  mortality  rate  of  107.3/100,000
men  and 50.6/100,000  women,  and  thus,  PAD  also  repre-
sents  a  public health  concern.7,8 The  aim  of  this  study  was  to
establish  the  prevalence  of  PAD  using the  ABI  to  screen  sub-
jects  over the  age of  40  years  from  the department  of  Cauca,
Colombia.  In  addition,  the association  between  sociodemo-
graphic  and  traditional  CVD  risk  factors  and  PAD  risk  was
estimated.
Methods
Study  design  and  population
This cross-sectional,  population-based  study  was  conducted
between  June  of 2011  and  May  of  2013  in 36  municipalities
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from  the  department  of  Cauca,  located  at  the  southwest
of  Colombia.  Corresponding  media  through  television,  radio
and  newspapers  was  used to  recruit  population  participants.
All  attending  subjects  who  agreed  to  participate  in  the
study  were  screened  and surveyed.  Inclusion  criteria  were
men  or women  over  the age  of  40  years,  regardless  of pro-
venance.  All  the questionnaires,  procedures,  and  protocols
were  reviewed  and  approved  by  the Ethics  Committee  for
Scientific  Research  at the  University  of  Cauca;  the  guidelines
used  in  the  review  were  based on  the bioethical  princi-
ples  established  in the  Helsinki  in 1975  declaration  and  the
parameters  outlined  in  Resolution  8430  of  the Colombian
Ministry  of Health  in 1993.
Data  collection
After  signing  a  consent  form,  each  volunteer  was  inter-
viewed  by  a  trained  health  professional  to  fill  out a
structured  questionnaire  to  establish  socio-demographical
characteristics  (age,  gender,  provenance,  educational  level,
and  occupational  status),  personal  clinical  history  (hyper-
tension,  diabetes,  dyslipidemia,  obesity,  acute  myocardial
infarction  and  brain  ischemia),  and  smoking  habits  (never,
former,  current).  During  examination,  height,  weight,  and
resting  blood  pressure  were measured  to  establish  the
presence  of  cardiovascular  risk  factors.  Thus,  arterial
hypertension  was  considered  when  having  systolic  arterial
pressure  ≥140  mm  Hg  and/or  a diastolic  arterial  pressure
≥90  mm  Hg.  Body  mass index (BMI)  was  calculated  as  weight
divided  by  squared  height  (kg/m2).  Subjects  were  divided
in  three  weight  categories:  normal  weight  (BMI  less  than
25),  overweight  (25--29.99)  and  obesity  (≥30).  In order  to
corroborate  the presence  of  personal  risk  factors,  blood
samples  were  drawn  for  biochemical  analyses  and medical
records  were  reviewed  for  clinical  diagnosis.  Thus,  subjects
were  considered  to  have  dyslipidemia  if they  had  a  fas-
ting  cholesterol  level  ≥200  mg/dL,  HDL  level  <40  mg/dL  for
men  and  <50  mg/dL  for  women, or  triglycerides  ≥150  mg/dL
(hypertriglyceridemia),  or  with  a  previous  diagnosis  of
hypercholesterolemia  or  were under  medication  use.  For
the  biochemical  analyses,  LDL-cholesterol  >100  mg/dL  was
considered  high  and a  low HDL-cholesterol  (<40  mg/dL,
for both  gender)  was  considered  hypoalphalipoproteinemia.
The  lipid  triad  was  defined  as  triglycerides  ≥150  mg/dL,
HDL-cholesterol  <40 mg/dL  (man)  or  <50  mg/dL  (women),
and  LDL-cholesterol  >100  mg/dL.  A  triglycerides  to  HDL-
cholesterol  ratio (TG/HDL-c)  >4  was  considered  as  elevated.
Diabetes  was  defined  as  having  a  fasting  glucose  level
≥126  mg/dL,  clinical  history  of  diabetes  or  diabetes  treat-
ment.
ABI  measurement
Patients  were  asked  to  rest  in a supine  position  for  10  min.
Afterwards,  the  systolic  blood  pressure  (SBP)  was  measured
in  the  brachial  artery  for  each  arm,  using  a sphygmo-
manometer  (WelchAllyn)  and  an 8-mHz  Doppler  device
(Huntleigh  500  D, Huntleigh  Technology).  The  cuff  was  then
placed  in  the  distal calf  and  the Doppler  was  used to  deter-
mine  the  SBP  of  both  posterior  tibial  and  dorsalis  pedis
arteries  of  each lower  limb.  The  ABI  for  each leg  was
calculated  by  dividing  the higher  of  the posterior  tibial  or
dorsalis  pedis pressure  by  the  higher  of  the  right  or  left
arm  SBP.  According  to  the recommendations  of  the Ameri-
can  Heart  Association  PAD  was  defined  as  having  an ABI  ≤  0.9
in  either  leg,  between  0.91  and  1.40  was  considered  nor-
mal,  and  when  >1.4  was  classified  as  suggestive  of  calcified
non-compressible  arteries.3 The  lower  of the two  ABI  values
obtained  was  used  for  the  diagnosis  of  PAD.  All  sphygmo-
manometers  were  calibrated  for  the  study  and  the ABI  test
was  performed  by  trained  health  professionals.
Statistical  analysis
Data  analyses  were  performed  using  SPSS  version  19.0  (SPSS
Inc.,  Chicago,  IL,  USA).  Prevalence  of  PAD  was  estimated  as
the  number  of subjects with  an  ABI  ≤  0.9  over  the  total  num-
ber  of subjects  collected  in the study.  Continuous  variables
were  expressed  using  the  mean  and  the  standard  deviation
and  the Student’s  t-test  was  used to  assess  mean  differences
between  study  groups.  Discrete  variables  were  expressed
as frequencies  and proportions  and the  Chi-squared  test
was  used  to assess  distribution  differences.  To  determine
the association  between  each variable  and disease  status,
subjects  with  ABI  > 1.4  were excluded  and  conditional  logis-
tic  regression  analysis  was  carried  out  to  calculate  both
crude  odds  ratios  (ORs)  and 95%  confidence  intervals  (CIs).  To
assess  the effect  of  potential  confounders,  ORs  were  initially
adjusted  in the model by  adding  as  covariates  age  (in  years
as  a  continuous  variable),  gender  (males  vs.  females),  and
provenance  (urban  vs.  rural).  For further  analysis,  ORs were
fully  adjusted  in a multivariate  model  adding  as  categori-
cal  variables  occupation  status,  education  level,  cigarette
smoking,  obesity,  hypertension,  diabetes,  and  dyslipidemia.
Interactions  between  risk  factors  were  evaluated  for  those
showing  a  significant  increase  on  PAD  risk.  The  interaction
analysis  was  carried  out  using the  macros  of the SPSS  sta-
tistical  package.9 A probability  level of  <0.05  was  used as
the  criterion  of significance.  Significance  levels  (p  values)
correspond  to  two-sided  tests.
Results
A total  of  10,000  subjects  were  screened  for  PAD.  As shown
in  Fig.  1,  the  prevalence  of  PAD  increased  with  aging  and
was  consistently  higher  in females  compared  to  males  in
all groups,  except  for  those  40--49  years  of  age.  Table 1
shows  the prevalence  of  PAD  in the  total  population  strat-
ified  by  demographic  variables  and  presence  of  CVD  risk
factors.  The  overall  prevalence  of  PAD  was  4.4%; 4.0%  in
male and 4.7%  in females.  PAD  was  equally  prevalent  in
urban  and  rural  communities.  As expected,  aging  sharply
increased  PAD  prevalence  from  a  low rate  of  0.5%  in sub-
jects  40--49  years  up  to  13.8%  and 16.3%  in subjects 70--79
and  ≥80  years,  respectively.  Furthermore,  PAD  subjects
were  more  often  diabetic  (23%),  hypertensive  (10.4%),  dys-
lipidemic  (10.4%),  unschooled  (8.7%),  obese  (7.4%),  and
current/former  cigarette  smokers  (6.3%).  Finally,  the  preva-
lence  of  PAD  among individuals  self-reporting  a history  of
acute  myocardial  infarction  or  stroke  was  31.0%  and  8.1%,
respectively.
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Table  1  Prevalence  of  PAD  by  selected  population  characteristics.
Total  n  (%)  n  PAD  %  (95%  CI)  p-Valuea
Gender
Male  4075  (41)  163  4.0  (3.40--4.60)
Female  5925  (59)  277  4.7  (4.16--5.24)  0.106
Provenance
Urban 6976  (70)  304  4.4  (3.92--4.88)
Rural 3024  (30)  136  4.5  (3.76--5.24)  0.755
Age group
40--49  1790  (18)  9 0.5  (0.17--0.83)
50--59 2941 (29) 29  1.0  (0.64--1.36)
60--69 3145 (31) 92  2.9  (2.31--3.49)
70--79 1441  (14)  199  13.8  (12.02--15.58)
≥ 80  683  (7) 111  16.3  (13.53--19.07)  0.001
Education level
None  494  (5) 43  8.7  (6.21--11.19)
Primary  school 4007  (40)  257  6.4  (5.64--7.16)
Secondary  school 3403  (34) 89  2.6  (2.07--3.13)
Technical/University 2096  (21)  51  2.4  (1.74--3.06)  0.001
Cigarette  smoking
Never  6381  (64)  212  3.3  (2.86--3.74)
Current/former  3619  (36)  228  6.3  (5.51--7.09)  0.001
Obesity
No 8548  (85)  332  3.9  (3.11--4.37)
Yes 1452  (15)  108  7.4  (6.05--8.75)  0.001
Hypertension
No 6346  (63)  59  0.9  (0.67--1.13)
Yes 3654  (37)  381  10.4  (9.41--11.39)  0.001
Diabetes
No 9604  (96)  349  3.6  (3.23--3.97)
Yes 396  (4) 91  23.0  (18.86--27.14)  0.001
Dyslipidemia
No 7400  (74)  169  2.3  (1.96--2.64)
Yes 2600 (26)  271  10.4  (9.23--11.57)  0.001
Self-reported  history  of acute  myocardial  infarction
No  9774  (98)  370  3.8  (3.42--4.18)
Yes 226  (2) 70  31.0  (24.97--37.03)  0.001
Self-reported  history  of stroke
No 9876  (99)  430  4.4  (4.00--4.80)
Yes 124  (1) 10  8.1  (3.30--12.90)  0.045
CI: confidence interval; PAD: peripheral arterial disease.
a Chi-squared p-value for the distribution between PAD and no PAD subjects.
In order  to  estimate  the odds  ratio  (OR)  for  each  of  the
above-mentioned  CVD  risk  factors,  442 subjects  with  ABI
>1.4  were  excluded.  Thus,  a  total  of  3853  (40.3%)  males
with  a  mean  age  of 61.48 years  (SD:  11.26  years)  and
5705  (59.7%)  females  with  a  mean  age  of 60.37  years  (SD:
11.46  years)  were  included  in this analysis.  As  shown  in
Table  2,  unschooling,  cigarette  smoking,  obesity,  hyperten-
sion,  diabetes  and  dyslipidemia  were  significantly  associated
to  an  increase  in risk  for  PAD  in  the  crude  (unadjusted)
OR  model.  However,  after  adjusting  in the  multivariate
regression  model,  hypertension  (OR 4.6; 95%  CI  3.42--6.20),
diabetes  (OR  4.3;  95%  CI  3.17--5.75),  dyslipidemia  (OR  3.1;
95%  CI  2.50--3.88),  obesity  (OR  1.8;  95%  CI  1.37--2.30)  and
cigarette  smoking  (OR  1.6;  95%  CI  1.26--1.94)  were  signifi-
cantly  associated  to  an increase  on  PAD  risk.  In contrast,
attending  to  secondary  school  was  a  protective  factor  for
PAD,  reducing  the risk  by  30%  (OR  0.7;  95%  CI  0.46--0.98).
When  looking  at cigarette  smoking  frequency  among  PAD
cases  by age  groups  (Fig.  3),  cigarette  consumption  was
more  often  observed  among  subjects  older  than  60  years
of  age,  but  the  difference  between  the groups  was  not  sta-
tistically  significant  (p  =  0.107).  For  the  lipid  profile  analysis
(Table 3), the TG/HDL  ratio was  strongly  associated  to  PAD
(OR  4.7; 95%  CI 3.9--7.9),  followed  by  the  lipid  triad  (OR
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Table  2  Selected  CVD  risk  factors  and  odds  ratio  (95%  CIs)  for  PAD.
No PAD  PAD  Crude  OR Adjusted  ORa Adjusted  ORb
n  (%) n  (%)  95%  CI 95%  CI  95%  CI
Education  level
Technical/University  1975  (21.7)  51  (11.6)  1.0 1.0  1.0
Secondary  school  3172  (34.8)  89  (20.2)  1.1 (0.77--1.54)  0.8  (0.58--1.19)  0.7  (0.46--0.98)
Primary school  3551  (38.9)  257  (58.4)  2.8 (2.06--3.80)  1.4  (0.99--1.94)  0.9  (0.65--1.30)
None 420  (4.6)  43  (9.8)  4.0 (2.61--6.03)  1.2  (0.76--1.95)  0.7  (0.46--1.23)
Cigarette smoking
Never  5905  (64.8) 212  (48.2) 1.0  1.0  1.0
Current/former  3213  (35.2) 228  (51.8) 2.0  (1.30--2.50) 1.7  (1.41--2.13) 1.6  (1.26--1.94)
Obesity
No 7864  (86.2)  332  (75.5)  1.0 1.0  1.0
Yes 1254  (13.8)  108  (24.5)  2.0 (1.63--2.55)  2.5  (1.93--3.14)  1.8  (1.37--2.30)
Hypertension
No 6057  (66.4)  59  (13.4)  1.0 1.0  1.0
Yes 3061  (33.6)  381  (86.6)  12.7  (9.68--16.87)  7.1  (5.34--9.47)  4.6  (3.42--6.20)
Diabetes
No 8846  (97.0) 349  (79.3) 1.0 1.0 1.0
Yes 272  (3.0) 91  (20.7) 8.5  (6.54--11.00) 6.5  (4.90--8.67) 4.3  (3.17--5.75)
Dyslipidemia
No 6974  (76.5)  169  (38.4)  1.0 1.0  1.0
Yes 2144  (23.5)  271  (61.6)  5.2 (4.28--6.36)  4.5  (3.68--5.58)  3.1  (2.50--3.88)
a Adjusted for age, gender and provenance.
b Adjusted for age, gender, provenance, education level, cigarette smoking, obesity, hypertension, diabetes, and dyslipidemia.
Table  3  Lipid  profiles  and  odds  ratio  (95%  CIs)  for  PAD.
No PAD  PAD  Crude  OR Adjusted  ORa Adjusted  ORb
n (%)  n  (%)  95%  CI 95%  CI 95%  CI
Cholesterol
No  7065  (77.5) 242  (55.0)  1.0  1.0 1.0
Yes 2053 (22.5) 198  (45.0) 2.8  (2.21--3.38)  1.7 (1.51--3.11)  1. 7 (1.33--3.12)
HDL-c
No 8106  (88.9)  177  (40.2)  1.0  1.0 1.0
Yes 1012  (11.1)  263  (59.8)  11.9  (9.73--14.55)  6.2 (3.12--11.04)  3.9 (3.03--10.51)
Hypertriglyceridemia
No 6749  (74.0)  249  (56.6)  1.0  1.0 1.0
Yes 2369  (26.0)  191  (43.4)  2.8  (1.75--2.51)  2.9 (1.83--2.31)  3.4 (1.92--2.27)
LDL-c
No 3645  (40.0)  80  (18.2)  1.0  1.0 1.0
Yes 5473  (60.0)  360  (81.8)  3.0  (2.34--3.83)  2.8 (2.21--3.68)  2.1 (1.64--2.81)
Triglycerides/HDL
No 6753  (74.1)  158  (35.9)  1.0  1.0 1.0
Yes 2365  (25.9)  282  (64.1)  5.2  (3.75--7.63)  5.0 (3.97--7.89)  4.7 (3.98--7.94)
Hypoalphalipoproteinemia
No 8910  (97.7)  371  (84.3)  1.0  1.0 1.0
Yes 208 (2.3)  68  (15.5)  5.0  (3.85--6.43)  4.5 (3.07--6.19)  4.0 (3.04--6.13)
Lipid triad
No  8210  (90)  194  (44.1)  1.0  1.0 1.0
Yes 908 (10)  246  (55.9)  11.5  (7.73--14.03)  6.3 (3.34--15.08)  4.1 (3.03--15.52)
a Adjusted for age, gender and provenance.
b Adjusted for age, gender, provenance, education level, cigarette smoking, obesity, hypertension, diabetes, and dyslipidemia.
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Figure  1 Prevalence  of  PAD  in  age  groups  by  gender.
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Figure  3  Frequency  of  cigarette  smoking  among  PAD  cases  by
age groups.
4.1;  95%  CI 3.0--15.5),  hypoalphalipoproteinemia  (OR  4.0;
95%  CI  3.0--6.1),  HDL-c  (OR  3.9;  95%  CI 3.0--10.5),  hyper-
triglyceridemia  (OR  3.4; 95%  CI  1.9--2.2),  LDL-c  (OR  2.1;
95%  CI  1.6--2.8),  and  cholesterol  (OR  1.7;  95%  CI  1.3--3.1),
respectively.
When  looking  at the  frequency  of  harbored  risk  factors  in
the  study  population  (Fig.  2), 94.1%  of  the  PAD  prevalence
was  explained  by  having  a combination  of two  or  more  risk
factors.  In  order  to  establish  which  combination  of risk  fac-
tors  exerted  the highest  increase  on PAD risk,  an interaction
analysis  was  conducted  (Table  4).  As  shown  for  the pairwise
interactions  in the adjusted  OR  model,  subjects  who  were
both  diabetic  and  dyslipidemic  showed  the  highest  PAD  risk
(OR  7.5;  95%  CI 5.1--11.0),  followed  by  diabetic  and smok-
ers  (OR  7.3;  95%  CI 5.0--10.8),  and  diabetic  and obese  (OR
7.1;  95%  CI  4.2--11.9).  Risk  evaluation  for  having  the inter-
action  of  three  or  more  risks  factors  showed  that  diabetes,
dyslipidemia  and  obesity  accounted  for  13.2  times  the risk
for  PAD  (95% CI  6.9--25.4),  and when adding  hypertension
to  the  model,  the risk  effect  was  the highest  (OR  17.2;  95%
CI  8.4--35.1).  Finally, when  adding  current/former  cigarette
smoking  as  the fifth  risk  factor  to  the model,  the associated
risk  was  decreased  but  it  still  remained  significant  (OR  8.2;
95%  CI  4.3--12.1).
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Figure  2  Distribution  of  number  CVD  risk  factors  on the  study
population.
Discussion
CVD are  the  leading  cause  of  death  in Latin  America,
with  ischemic  heart  disease  as  the  principal  cause  in most
countries.1 Global  attention  has  been  devoted  to  under-
standing  CVD;  however,  little  observance  has  been  dedicated
to  PAD  as  few  epidemiological  studies  have  been  conducted,
especially  in  low or  middle-income  countries.  Colombia  is
experiencing  a  rapid  population  growth,  being  today  the
third-most  densely  inhabited  country  in Latin  America  after
Mexico  and  Brazil.  In  addition,  years  of  armed  conflict  have
obligated  thousands  of  people  to  migrate  from  rural  to  urban
areas,  a phenomenon  that  has  affected  their  access  to  edu-
cation,  basic  needs  and health  care.10 While  the  ongoing
recovering  of  Colombia’s  economy  has improved  the liv-
ing  standards  in urban  areas,  the population  exposure  to
environmental  and  life  style  risk  factors  such  as  poor diet,
cigarette  consumption,  and physical  inactivity,  among  oth-
ers has  also increased.11 Therefore,  disease  pattern  and
level  of exposure  to  risk  factors  vary depending  on  the  par-
ticular  conditions  of  each  country,  and thus,  the  strategies  to
prevent  and  control  disease  burden  cannot  be  transversally
applied.
In  the  present  study,  the  overall  prevalence  of  PAD  was
4.4%,  being  higher  among  women  (4.7%)  compared  to  men
(4.0%)  but  consistently  increasing  with  aging  in both  gen-
ders  (Fig.  1).  This  observed  overall  PAD  prevalence  is  lower
than  the  previously  reported  for other  Latin  American  stud-
ies  conducted  in Ecuador  (7%),  Brazil  (10.5%),  and  Mexico
(10%).12--14 The  observed  differences  might  be due, in  part,
to  selection  criteria,  population  characteristics,  study  set-
ting  (rural  vs.  urban),  and  sample  size.  However,  these
differences  may,  in  fact,  reflect  precisely  across-countries
variation  on  population  exposure  to  know  risk  factors  such
as  smoking,  hypertension,  dyslipidemia,  diabetes,  obesity
and  history  of CVD.15 As stated  before,  the  migration  from
rural  to  urban  settings  is  increasingly  exposing  the Colom-
bian  population  to  CVD  risk  factors,  and  thus,  the  observed
PAD  prevalence  although  low,  raises  important  public  health
challenges  to  control  and  manage  CVD  burden.
With  regards  to  gender, our  results  are consistent  with  a
recent  meta-analysis,  including  34  community-based  studies
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Table  4  Interaction  between  selected  CVD  risk  factors  and  odds  ratio  (95%  CIs)  for  PAD.
Crude  OR  95%  CI Adjusted  ORa 95%  CI
Hypertension*Diabetes  10.4  (7.9--13.9)  6.3  (4.5--8.7)
Hypertension*Dyslipidemia  8.0  (6.5--9.7)  5.2  (4.2--6.4)
Hypertension*Obesity  5.2  (4.0--6.7)  3.2  (2.5--4.2)
Hypertension*Smoking  5.7  (4.7--7.0)  3.5  (2.8--4.3)
Diabetes*Dyslipidemia  9.8  (7.1--13.7)  7.5  (5.1--11.0)
Diabetes*Obesity  7.1  (4.5--11.1)  7.1  (4.2--11.9)
Diabetes*Smoking  9.2  (6.5--12.9) 7.3  (5.0--10.8)
Dyslipidemia*Obesity  4.5  (3.4--5.9) 4.1  (3.0--5.6)
Dyslipidemia*Smoking  4.2  (3.4--5.2) 3.4  (2.7--4.2)
Obesity*Smoking  2.3  (1.6--3.2)  2.3  (1.6--3.3)
Hypertension*Diabetes*Dyslipidemia  13.0  (9.0--18.8)  9.1  (6.0--13.7)
Hypertension*Diabetes*Obesity  10.1  (6.2--16.4)  10.1  (5.9--17.  1)
Hypertension*Diabetes*Smoking  11.0  (4.3--16.1)  7.1  (4.6--14.9)
Hypertension*Dyslipidemia*Obesity  5.8  (4.3--7.8) 5.4  (3.9--7.5)
Hypertension*Dyslipidemia*Smoking  7.0  (5.6--8.9) 4.6  (3.5--5.9)
Hypertension*Obesity*Smoking  4.5  (3.2--6.3) 4.0  (2.7--5.7)
Diabetes*Dyslipidemia*Obesity  11.4  (6.4--20.3) 13.2  (6.9--25.4)
Diabetes*Dyslipidemia*Smoking  10.5  (6.5--17.0)  9.5  (5.6--16.1)
Dyslipidemia*Obesity*Smoking  3.6  (2.3--5.5)  3.7  (2.3--5.8)
Hypertension*Diabetes*Dyslipidemia*Obesity  15.2  (8.1--28.5)  17.2  (8.4--35.1)
Hypertension*Diabetes*Dyslipidemia*Smoking  11.4  (4.7--18.2)  9.7  (5.7--16.2)
Hypertension*Diabetes*Obesity*Smoking  10.6  (5.1--22.0)  11.8  (5.4--25.6)
Diabetes*Dyslipidemia*Obesity*Smoking  9.9  (4.2--23.1)  11.3  (4.5--28.35)
Hypertension*Diabetes*Dyslipidemia*Obesity*Smoking  10.2  (3.6--14.3)  8.2  (4.3--12.1)
CI: confidence interval; PAD: peripheral arterial disease; OR: odds ratio.
a Adjusted for age, gender, provenance, and education level.
with  a  total  of  112,027  individuals,  showing  that  in low  or
middle-income  countries,  PAD  prevalence  was  consistently
higher  in  women  compared  to men  up  to  85--89 years  of
age,  although  the  difference  narrowed  with  aging.1 These
gender-based  prevalence  differences  could  be  related  to
‘‘unidentified  risk  factors’’  or  might  represent  a  survival
advantage  for  women,  with  men  being  more  likely  to  expe-
rience  death  from  concomitant  coronary  heart  disease.15 In
addition,  our study  shows,  as  well  as  in many  others,  that
the  ABI  increased  with  aging.2--4 This  is  probably  due  to  an
increased  prevalence  of other  atherosclerosis  risk  factors
with  aging,  which  also  triggers  the progression  of  PAD.16,17
Furthermore,  our  study  confirms  the role  of traditional  CVD
risk  factors  on  PAD  prevalence  (Table  1),  which  have  been
consistently  reported  as  major  predictors  of  morbidity  and
mortality,18 and  support  the argument  for  PAD  prevalence
variation  depending  on  the  population  distribution  of CVD
risk  factors.1,15 Finally,  our  results  corroborate  previously
reported  observations  of  a cross-sectional  study  conducted
in  Bucaramanga,  Colombia.  This  established  the prevalence
of  CVD  risk  factors  in a random  sample  of  the general  popula-
tion  (2989  subjects,  15--64  years  old),  showing  that  smoking,
hypertension,  obesity,  high  cholesterol,  and diabetes  were
significantly  prevalent,  calling  for  actions  to  control  the
ongoing  CVD  epidemic.19
Based  upon  our  data  (Table  2),  an  alarming  increase  in
CVD  could  be  expected  in the coming  decades  in the study
population,  as  smoking,  hypertension,  dyslipidemia,  and
obesity  were  quite  prevalent  among  non-PAD  subjects  with
proportions  of  35.2,  33.6,  23.5,  and 13.8%,  respectively.
Among  PAD  cases,  hypertension  was  the strongest  predictor
for  disease  risk  with  an  adjusted  OR  of 4.9,  followed  by  dia-
betes  >  dyslipidemia  > obesity.  In  particular,  our  study  shows
that  the TG/HDL  ratio  was  the most  important  contribu-
tor  to  dyslipidemia,  increasing  the  risk  for  PAD  in  4.7-times
after  adjustment  (Table 3),  which  is  also  consistent  with
previous  studies  indicating  that  the  TG/HDL  ratio  is  a pow-
erful  independent  indicator  of  extensive  coronary  artery
disease,  heart  failure,  and  atherosclerosis.20--22 On the other
hand,  our  study  shows  that  cigarette  smoking  was  weakly
associated  to  PAD,  increasing  the risk  to  1.6  times  (95%  CI
1.35--2.02)  in the adjusted  OR  model.  Worldwide,  cigarette
smoking  is  the  most  important  risk  factor  associated  to  PAD,
increasing  the  risk  for  the  disease  in up to  7 times  compared
to  non-smokers.23 However,  our  results  are consistent  with  a
recent  meta-analysis  study  showing  that  cigarette  smoking
is  strongly  associated  to  PAD  in  high  income  countries  (meta-
OR  for current  smoking  of  2.72;  95%  CI 2.39--3.09)  while  in
low or  middle  income  countries,  as  is  the  case  for  Colombia,
cigarette  smoking  plays  a  lesser  role  (meta-OR  1.42;  95%  CI
1.2--1.62).1 Finally, PAD  subjects  reported  more  often  hav-
ing  a history  of  acute  myocardial  infarction  (31%)  and  stroke
(8.1%).  In a follow-up  study,  it  was  previously  established
that PAD  patients  present  a 3.1-times  increase  in risk  for
death  from  all  causes,  5.9  from  CVD,  and  6.6  from  coro-
nary  heart  disease.15--19,24 Altogether,  our  results  suggest  the
use  of  ABI  as  a sensible,  low cost  method  to  indirectly  sus-
pect  the presence  of  atherosclerotic  events  in  other  arterial
beds,  which  can  help  to  implement  intervention  and  follow-
up  strategies  among  individuals  with  medium  to  high  risk  for
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CVD.  Such  recommendation  is  also  supported  by  other  stud-
ies  that  proclaim  the use  of the ABI  in  primary  health  care
for  early  identification  of PAD  in populations  with  prevailing
CVD  risk  factors.25--27
In addition  to  establishing  the  distribution  of traditional
CVD  risk  factors  and  their  effect  on  PAD  risk, we  investigated
the  frequency  distribution  of harboring  a combination  of  CVD
risk  factors  on  PAD  subjects  (Fig.  2). Accordingly,  the major-
ity  of  PAD  subjects  harbored  the  presence  of  three  (35.2%)
or  four  (30%)  CVD  risk  factors  and  a lesser percentage  pre-
sented  five  (11.6%)  simultaneously.  This  observation  may  be
partly  explained  by  the  fact  that  the sample  for  subjects  har-
boring  three  or  four CVD  risk  factors  had  a higher  number  of
individuals,  thus,  allowing  for  a greater  identification  of  PAD
cases  within  these  categories.  It could  also  be  related  to  a
reduction  of  life  expectancy  among subjects  harboring  five
CVD  risk  factors  compared  to  the other  those  in the three
or  four  CVD  risk  factors’  categories  (Mean  age 71.94  ±  8.37
vs.  74.51  ± 8.98,  respectively,  p =  0.058),  which  could  lead
to  underestimating  PAD  prevalence  given  the less  number  of
subjects  on  this group.
It  should  be  noted  that  in our  study  population  the four
most  important  risk  factors  for  PAD were  hypertension,  dia-
betes,  dyslipidemia,  and obesity,  increasing  the  disease  risk
up  to  17.2-times  (Table  4).  On  the other  hand,  cigarette
smoking  did  not  contribute  to  a  significant  increase  in PAD
risk,  as it could  have  been  expected  when  adding  it  as  the
fifth  interaction  term  in the model,  but  it rather reduced
the  risk.  The  higher  effect  of  obesity  compared  to  cigarette
smoking  on  PAD  risk  when interacting  with  hypertension,
diabetes  and  dyslipidemia  highlights  the  importance  of  con-
trolling  poor  diet and  irregular  physical  exercise  to  manage
PAD.  The  lower  risk  effect  of  smoking  could  be  due  to  sub-
ject’s  self-awareness  to  consume  fewer  cigarettes  when
presenting  multiple  risk  factors  or  subjects  being  less  capa-
ble  of  economically  sustaining  the habit  while  having  to
invest  on  medication  to  treat  other  health  conditions.  A
review  on  the  relationship  between  obesity  and  smoking28
indicates  that  an  inverse  relationship  between  these  two
factors  has  been  established  by  epidemiological  studies,29
as  in  the  general  population,  smokers  usually  weigh  less
than  non-smokers.30 However,  obese  smokers  tend  to  con-
sume  more  cigarettes  due  to the  reinforcement  effect  of
nicotine  and  are  at  higher  risk  given  the  simultaneous  pres-
ence  of other  lifestyle  risk  factors,  including  low fruit and
vegetable  intake,  less  physical  activity  and  higher  alcohol
consumption.28 In  the  present  study,  a dose-response  rela-
tionship  between  the number  of  cigarettes  smoked  per  year
and  the  increase  in risk  of  PAD  was  not  established.  There-
fore,  we  cannot  conclude  with  certainty  about  the effect
of  cigarette  smoking  exposure  level  or  its  interaction  with
other  CVD  risk  factors  on  PAD  risk  in the study  population.
Our  study  presented  some  limitations,  including:  (a)
study  population  was  not recruited  at  random  but  rather  by
convenience,  and  thus,  our  observations  might  not  entirely
represent  the  general  population;  (b)  although  the ABI  test
has  been  validated  and widely  used for  the screening  of
PAD  and  prediction  of  CVD,  additional  evaluation  through
Doppler  ultrasound  would  have  been  recommended  for a
more  accurate  diagnose  of PAD  cases;  (c)  finally,  data  on  the
number  of  cigarettes  and  years  of  exposure  were  not col-
lected,  and thus, the risk  posed  by  the intensity  of cigarette
consumption  on  PAD  was  not  estimated  in  the study  popu-
lation,  which  could  partly  explain  why  a strong  increase  in
risk  for  PAD  was  not observed  among  smokers.
This  epidemiological  study  represents,  to  the best of  our
knowledge,  the  largest  conducted  so  far  in Latino Amer-
ica  and  the first  community-based  cross-sectional  study  in
Colombia  using  the  ABI  to  establish  the  prevalence  of  PAD  in
an  adult  population.  We  conclude  that  PAD  prevalence  was
relatively  low (4.4%),  considering  the  overall  mean  age of
the  study  population  (61  ±  11.4  yrs)  and the prevalence  dis-
tribution  of  traditional  CVD  risk  factors.  However,  our  study
confirms  the  role  of  these  factors  on  disease  risk,  favors  the
argument  for  PAD  prevalence  variation  depending  on  CVD
risk  factor  distribution,  and supports  the  use  of  ABI  mea-
surement  for  PAD  diagnosis  among  intermediate  to  high-risk
patients.  Therefore,  these observations  are  of  relevance
for  clinicians  as, based  upon  our  results,  patients  can be
early  identified  at higher  CVD  disease  risk  to  receive  a  more
immediate  intervention.  Finally,  given  the strong,  interac-
tion  effect  between  hypertension,  diabetes,  dyslipidemia,
and  obesity  on  the risk  of  PAD,  our  results  provide  scientific
evidence  for  local  health  authorities  to  support the  need  for
better  policies  and  strategies  aimed  to  prevent  and  control
the  observed  risk  factors  for  reducing  CVD  burden.
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